Transmethylation in immunity and autoimmunity

Clinical Immunology

Volumn 143, Issue 1, 2012, Pages 8-21

  Lawson, Brian R ^a   Eleftheriadis, Theodoros ^a   Tardif, Virginie ^a   Gonzalez Quintial, Rosana ^a   Baccala, Roberto ^a   Kono, Dwight H ^a   Theofilopoulos, Argyrios N ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Autoimmunity; EAE; Lupus; T cells; Transmethylation

Indexed keywords

4',5' DIDEHYDRO 5' DEOXY 5' FLUOROADENOSINE; ADENOSYLHOMOCYSTEINASE; ADENOSYLHOMOCYSTEINASE INHIBITOR; DNA METHYLTRANSFERASE INHIBITOR; DZ 2002; NUCLEIC ACID; PROTEIN ARGININE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; DELAYED HYPERSENSITIVITY; ENCEPHALOMYELITIS; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; HUMAN; IMMUNOSTIMULATION; METHYLATION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THYMUS; TRANSMETHYLATION;

ANIMALS; AUTOIMMUNITY; HUMANS; IMMUNE SYSTEM; IMMUNITY; METHYLATION; MODELS, IMMUNOLOGICAL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; THYMOCYTES;

EID: 84858081105     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.10.007     Document Type: Review

References (98)

1. Mamula M.J., Gee R.J., Elliott J.I., Sette A., Southwood S., Jones P.J., Blier P.R. Isoaspartyl post-translational modification triggers autoimmune responses to self-proteins. J. Biol. Chem. 1999, 274:22321-22327.
2. Banerjee A.K. 5'-terminal cap structure in eucaryotic messenger ribonucleic acids. Microbiol. Rev. 1980, 44:175-205.
3. Chiang P.K., Gordon R.K., Tal J., Zeng G.C., Doctor B.P., Pardhasaradhi K., McCann P.P. S-adenosylmethionine and methylation. FASEB J. 1996, 10:471-480.
4. Ueland P.M., Helland S., Broch O.J., Schanche J.S. Homocysteine in tissues of the mouse and rat. J. Biol. Chem. 1984, 259:2360-2364.
5. Miller M.W., Duhl D.M., Winkes B.M., Arredondo-Vega F., Saxon P.J., Wolff G.L., Epstein C.J., Hershfield M.S., Barsh G.S. The mouse lethal nonagouti (a(x)) mutation deletes the S-adenosylhomocysteine hydrolase (Ahcy) gene. EMBO J. 1994, 13:1806-1816.
6. Baric I., Cuk M., Fumic K., Vugrek O., Allen R.H., Glenn B., Maradin M., Pazanin L., Pogribny I., Rados M., Sarnavka V., Schulze A., Stabler S., Wagner C., Zeisel S.H., Mudd S.H. S-adenosylhomocysteine hydrolase deficiency: a second patient, the younger brother of the index patient, and outcomes during therapy. J. Inherit. Metab. Dis. 2005, 28:885-902.
7. Baric I., Fumic K., Glenn B., Cuk M., Schulze A., Finkelstein J.D., James S.J., Mejaski-Bosnjak V., Pazanin L., Pogribny I.P., Rados M., Sarnavka V., Scukanec-Spoljar M., Allen R.H., Stabler S., Uzelac L., Vugrek O., Wagner C., Zeisel S., Mudd S.H. S-adenosylhomocysteine hydrolase deficiency in a human: a genetic disorder of methionine metabolism. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:4234-4239.
8. Buist N.R., Glenn B., Vugrek O., Wagner C., Stabler S., Allen R.H., Pogribny I., Schulze A., Zeisel S.H., Baric I., Mudd S.H. S-adenosylhomocysteine hydrolase deficiency in a 26-year-old man. J. Inherit. Metab. Dis. 2006, 29:538-545.
9. Blanchet F., Schurter B.T., Acuto O. Protein arginine methylation in lymphocyte signaling. Curr. Opin. Immunol. 2006, 18:321-328.
10. Zhang X., Cheng X. Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides. Structure 2003, 11:509-520.
11. Lin W.J., Gary J.D., Yang M.C., Clarke S., Herschman H.R. The mammalian immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase. J. Biol. Chem. 1996, 271:15034-15044.
12. Pal S., Vishwanath S.N., Erdjument-Bromage H., Tempst P., Sif S. Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol. Cell. Biol. 2004, 24:9630-9645.
13. Singh V., Miranda T.B., Jiang W., Frankel A., Roemer M.E., Robb V.A., Gutmann D.H., Herschman H.R., Clarke S., Newsham I.F. DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo. Oncogene 2004, 23:7761-7771.
14. Bedford M.T., Richard S. Arginine methylation an emerging regulator of protein function. Mol. Cell. 2005, 18:263-272.
15. McBride A.E., Silver P.A. State of the arg: protein methylation at arginine comes of age. Cell 2001, 106:5-8.
16. Le Romancer M., Treilleux I., Leconte N., Robin-Lespinasse Y., Sentis S., Bouchekioua-Bouzaghou K., Goddard S., Gobert-Gosse S., Corbo L. Regulation of estrogen rapid signaling through arginine methylation by PRMT1. Mol. Cell. 2008, 31:212-221.
17. Chan J.Y., Hsieh T.Y., Liu S.T., Chou W.Y., Chung M.H., Huang S.M. Physical and functional interactions between hnRNP K and PRMT family proteins. FEBS Lett. 2009, 583:281-286.
18. Bruns A.F., Grothe C., Claus P. Fibroblast growth factor 2 (FGF-2) is a novel substrate for arginine methylation by PRMT5. Biol. Chem. 2009, 390:59-65.
19. Kim J.D., Kako K., Kakiuchi M., Park G.G., Fukamizu A. EWS is a substrate of type I protein arginine methyltransferase, PRMT8. Int. J. Mol. Med. 2008, 22:309-315.
20. Pahlich S., Zakaryan R.P., Gehring H. Identification of proteins interacting with protein arginine methyltransferase 8: the Ewing sarcoma (EWS) protein binds independent of its methylation state. Proteins 2008, 72:1125-1137.
21. Pike M.C., DeMeester C.A. Inhibition of phosphoinositide metabolism in human polymorphonuclear leukocytes by S-adenosylhomocysteine. J. Biol. Chem. 1988, 263:3592-3599.
22. Pike M.C., Kredich N.M., Snyderman R. Requirement of S-adenosyl-l-methionine-mediated methylation for human monocyte chemotaxis. Proc. Natl. Acad. Sci. U. S. A. 1978, 75:3928-3932.
23. Pike M.C., Snyderman R. Transmethylation reactions are required for initial morphologic and biochemical responses of human monocytes to chemoattractants. J. Immunol. 1981, 127:1444-1449.
24. German D.C., Bloch C.A., Kredich N.M. Measurements of S-adenosylmethionine and l-homocysteine metabolism in cultured human lymphoid cells. J. Biol. Chem. 1983, 258:10997-11003.
25. Tsuchiya S., Nakae S., Konno T., Tada K. S-adenosylhomocysteine hydrolase activity in a lymphoblastoid cell line from a patient with adenosine deaminase deficiency disease. J. Inherit. Metab. Dis. 1981, 4:197-201.
26. Cohen A., Hirschhorn R., Horowitz S.D., Rubinstein A., Polmar S.H., Hong R., Martin D.W. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc. Natl. Acad. Sci. U. S. A. 1978, 75:472-476.
27. Ullman B., Cohen A., Martin D.W. Characterization of a cell culture model for the study of adenosine deaminase- and purine nucleoside phosphorylase-deficient immunologic disease. Cell 1976, 9:205-211.
28. Ullman B., Gudas L.J., Cohen A., Martin D.W. Deoxyadenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells: a model for immunodeficiency disease. Cell 1978, 14:365-375.
29. Wolos J.A., Frondorf K.A., Babcock G.F., Stripp S.A., Bowlin T.L. Immunomodulation by an inhibitor of S-adenosyl-l-homocysteine hydrolase: inhibition of in vitro and in vivo allogeneic responses. Cell. Immunol. 1993, 149:402-408.
30. Wolos J.A., Frondorf K.A., Davis G.F., Jarvi E.T., McCarthy J.R., Bowlin T.L. Selective inhibition of T cell activation by an inhibitor of S-adenosyl-l-homocysteine hydrolase. J. Immunol. 1993, 150:3264-3273.
31. Benveniste P., Zhu W., Cohen A. Interference with thymocyte differentiation by an inhibitor of S-adenosylhomocysteine hydrolase. J. Immunol. 1995, 155:536-544.
32. Kim J., Lee J., Yadav N., Wu Q., Carter C., Richard S., Richie E., Bedford M.T. Loss of CARM1 results in hypomethylation of thymocyte cyclic AMP-regulated phosphoprotein and deregulated early T cell development. J. Biol. Chem. 2004, 279:25339-25344.
33. Lambert L.E., Frondorf K.A., Berling J.S., Wolos J.A. Effects of an S-adenosyl-l-homocysteine hydrolase inhibitor on murine macrophage activation and function. Immunopharmacology 1995, 29:121-127.
34. Fu Y.F., Wang J.X., Zhao Y., Yang Y., Tang W., Ni J., Zhu Y.N., Zhou R., He P.L., Li C., Li X.Y., Yang Y.F., Lawson B.R., Zuo J.P. S-adenosyl-l-homocysteine hydrolase inactivation curtails ovalbumin-induced immune responses. J. Pharmacol. Exp. Ther. 2006, 316:1229-1237.
35. Fu Y.F., Zhu Y.N., Ni J., Zhong X.G., Tang W., Re Y.D., Shi L.P., Wan J., Yang Y.F., Yuan C., Nan F.J., Lawson B.R., Zuo J.P. A reversible S-adenosyl-l-homocysteine hydrolase inhibitor ameliorates experimental autoimmune encephalomyelitis by inhibiting T cell activation. J. Pharmacol. Exp. Ther. 2006, 319:799-808.
36. Lawson B.R., Manenkova Y., Ahamed J., Chen X., Zou J.P., Baccala R., Theofilopoulos A.N., Yuan C. Inhibition of transmethylation down-regulates CD4 T cell activation and curtails development of autoimmunity in a model system. J. Immunol. 2007, 178:5366-5374.
37. Wu Q.L., Fu Y.F., Zhou W.L., Wang J.X., Feng Y.H., Liu J., Xu J.Y., He P.L., Zhou R., Tang W., Wang G.F., Zhou Y., Yang Y.F., Ding J., Li X.Y., Chen X.R., Yuan C., Lawson B.R., Zuo J.P. Inhibition of S-adenosyl-l-homocysteine hydrolase induces immunosuppression. J. Pharmacol. Exp. Ther. 2005, 313:705-711.
38. Abramovich C., Yakobson B., Chebath J., Revel M. A protein-arginine methyltransferase binds to the intracytoplasmic domain of the IFNAR1 chain in the type I interferon receptor. EMBO J. 1997, 16:260-266.
39. Mowen K.A., Tang J., Zhu W., Schurter B.T., Shuai K., Herschman H.R., David M. Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription. Cell 2001, 104:731-741.
40. Komyod W., Bauer U.M., Heinrich P.C., Haan S., Behrmann I. Are STATS arginine-methylated?. J. Biol. Chem. 2005, 280:21700-21705.
41. Meissner T., Krause E., Lodige I., Vinkemeier U. Arginine methylation of STAT1: a reassessment. Cell 2004, 119:587-589. discussion 589-590.
42. Weber S., Maass F., Schuemann M., Krause E., Suske G., Bauer U.M. PRMT1-mediated arginine methylation of PIAS1 regulates STAT1 signaling. Genes Dev. 2009, 23:118-132.
43. Levy D., Kuo A.J., Chang Y., Schaefer U., Kitson C., Cheung P., Espejo A., Zee B.M., Liu C.L., Tangsombatvisit S., Tennen R.I., Kuo A.Y., Tanjing S., Cheung R., Chua K.F., Utz P.J., Shi X., Prinjha R.K., Lee K., Garcia B.A., Bedford M.T., Tarakhovsky A., Cheng X., Gozani O. Lysine methylation of the NF-kappaB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-kappaB signaling. Nat. Immunol. 2011, 12:29-36.
44. Blanchet F., Cardona A., Letimier F.A., Hershfield M.S., Acuto O. CD28 costimulatory signal induces protein arginine methylation in T cells. J. Exp. Med. 2005, 202:371-377.
45. Tybulewicz V.L. Vav-family proteins in T-cell signalling. Curr. Opin. Immunol. 2005, 17:267-274.
46. Prisco A., Vanes L., Ruf S., Trigueros C., Tybulewicz V.L. Lineage-specific requirement for the PH domain of Vav1 in the activation of CD4+ but not CD8+ T cells. Immunity 2005, 23:263-274.
47. Fischer K.D., Zmuldzinas A., Gardner S., Barbacid M., Bernstein A., Guidos C. Defective T-cell receptor signalling and positive selection of Vav-deficient CD4+ CD8+ thymocytes. Nature 1995, 374:474-477.
48. Tarakhovsky A., Turner M., Schaal S., Mee P.J., Duddy L.P., Rajewsky K., Tybulewicz V.L. Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav. Nature 1995, 374:467-470.
49. Zhang R., Alt F.W., Davidson L., Orkin S.H., Swat W. Defective signalling through the T- and B-cell antigen receptors in lymphoid cells lacking the vav proto-oncogene. Nature 1995, 374:470-473.
50. Wolos J.A., Frondorf K.A., Esser R.E. Immunosuppression mediated by an inhibitor of S-adenosyl-l-homocysteine hydrolase. Prevention and treatment of collagen-induced arthritis. J. Immunol. 1993, 151:526-534.
51. Saso Y., Conner E.M., Teegarden B.R., Yuan C.S. S-adenosyl-l-homocysteine hydrolase inhibitor mediates immunosuppressive effects in vivo: suppression of delayed type hypersensitivity ear swelling and peptidoglycan polysaccharide-induced arthritis. J. Pharmacol. Exp. Ther. 2001, 296:106-112.
52. Baccala R., Gonzalez-Quintial R., Lawson B.R., Stern M.E., Kono D.H., Beutler B., Theofilopoulos A.N. Sensors of the innate immune system: their mode of action. Nat. Rev. Rheumatol. 2009, 5:448-456.
53. Theofilopoulos A.N., Gonzalez-Quintial R., Lawson B.R., Koh Y.T., Stern M.E., Kono D.H., Beutler B., Baccala R. Sensors of the innate immune system: their link to rheumatic diseases. Nat. Rev. Rheumatol. 2010, 6:146-156.
54. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
55. Yang M.L., Doyle H.A., Gee R.J., Lowenson J.D., Clarke S., Lawson B.R., Aswad D.W., Mamula M.J. Intracellular protein modification associated with altered T cell functions in autoimmunity. J. Immunol. 2006, 177:4541-4549.
56. Doyle H.A., Zhou J., Wolff M.J., Harvey B.P., Roman R.M., Gee R.J., Koski R.A., Mamula M.J. Isoaspartyl post-translational modification triggers anti-tumor T and B lymphocyte immunity. J. Biol. Chem. 2006, 281:32676-32683.
57. Doyle H.A., Gee R.J., Mamula M.J. A failure to repair self-proteins leads to T cell hyperproliferation and autoantibody production. J. Immunol. 2003, 171:2840-2847.
58. Chang X., Yamada R., Suzuki A., Sawada T., Yoshino S., Tokuhiro S., Yamamoto K. Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatology (Oxford) 2005, 44:40-50.
59. Foulquier C., Sebbag M., Clavel C., Chapuy-Regaud S., Al Badine R., Mechin M.C., Vincent C., Nachat R., Yamada M., Takahara H., Simon M., Guerrin M., Serre G. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum. 2007, 56:3541-3553.
60. Mastronardi F.G., Wood D.D., Mei J., Raijmakers R., Tseveleki V., Dosch H.M., Probert L., Casaccia-Bonnefil P., Moscarello M.A. Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation. J. Neurosci. 2006, 26:11387-11396.
61. Rubin B., Sonderstrup G. Citrullination of self-proteins and autoimmunity. Scand. J. Immunol. 2004, 60:112-120.
62. Vossenaar E.R., Despres N., Lapointe E., van der Heijden A., Lora M., Senshu T., van Venrooij W.J., Menard H.A. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res. Ther. 2004, 6:R142-R150.
63. Vossenaar E.R., Radstake T.R., van der Heijden A., van Mansum M.A., Dieteren C., de Rooij D.J., Barrera P., Zendman A.J., van Venrooij W.J. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann. Rheum. Dis. 2004, 63:373-381.
64. Backlund J., Treschow A., Bockermann R., Holm B., Holm L., Issazadeh-Navikas S., Kihlberg J., Holmdahl R. Glycosylation of type II collagen is of major importance for T cell tolerance and pathology in collagen-induced arthritis. Eur. J. Immunol. 2002, 32:3776-3784.
65. Buzas E.I., Gyorgy B., Pasztoi M., Jelinek I., Falus A., Gabius H.J. Carbohydrate recognition systems in autoimmunity. Autoimmunity 2006, 39:691-704.
66. Opdenakker G., Dillen C., Fiten P., Martens E., Van Aelst I., Van den Steen P.E., Nelissen I., Starckx S., Descamps F.J., Hu J., Piccard H., Van Damme J., Wormald M.R., Rudd P.M., Dwek R.A. Remnant epitopes, autoimmunity and glycosylation. Biochim. Biophys. Acta 2006, 1760:610-615.
67. Meda F., Folci M., Baccarelli A., Selmi C. The epigenetics of autoimmunity. Cell. Mol. Immunol. 2011, 8:226-236.
68. Reik W., Dean W., Walter J. Epigenetic reprogramming in mammalian development. Science 2001, 293:1089-1093.
69. Li E., Beard C., Jaenisch R. Role for DNA methylation in genomic imprinting. Nature 1993, 366:362-365.
70. Mohandas T., Sparkes R.S., Shapiro L.J. Reactivation of an inactive human X chromosome: evidence for X inactivation by DNA methylation. Science 1981, 211:393-396.
71. Bird A.P. Functions for DNA methylation in vertebrates. Cold Spring Harb. Symp. Quant. Biol. 1993, 58:281-285.
72. Berger S.L. The complex language of chromatin regulation during transcription. Nature 2007, 447:407-412.
73. Li B., Carey M., Workman J.L. The role of chromatin during transcription. Cell 2007, 128:707-719.
74. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
75. Ohm J.E., Baylin S.B. Stem cell chromatin patterns: an instructive mechanism for DNA hypermethylation?. Cell Cycle 2007, 6:1040-1043.
76. Bannister A.J., Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011, 21:381-395.
77. Esteller M. The coming of age of DNA methylation in medicine in the genomics and postgenomics era. Clin. Immunol. 2002, 103:213-216.
78. Teitell M., Richardson B. DNA methylation in the immune system. Clin. Immunol. 2003, 109:2-5.
79. Cedar H., Bergman Y. Epigenetics of haematopoietic cell development. Nat. Rev. Immunol. 2011, 11:478-488.
80. Fitzpatrick D.R., Wilson C.B. Methylation and demethylation in the regulation of genes, cells, and responses in the immune system. Clin. Immunol. 2003, 109:37-45.
81. Inlay M., Xu Y. Epigenetic regulation of antigen receptor rearrangement. Clin. Immunol. 2003, 109:29-36.
82. Krangel M.S. Gene segment selection in V(D)J recombination: accessibility and beyond. Nat. Immunol. 2003, 4:624-630.
83. Whitehurst C.E., Schlissel M.S., Chen J. Deletion of germline promoter PD beta 1 from the TCR beta locus causes hypermethylation that impairs D beta 1 recombination by multiple mechanisms. Immunity 2000, 13:703-714.
84. Jenner R.G., Townsend M.J., Jackson I., Sun K., Bouwman R.D., Young R.A., Glimcher L.H., Lord G.M. The transcription factors T-bet and GATA-3 control alternative pathways of T-cell differentiation through a shared set of target genes. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:17876-17881.
85. Szabo S.J., Sullivan B.M., Peng S.L., Glimcher L.H. Molecular mechanisms regulating Th1 immune responses. Annu. Rev. Immunol. 2003, 21:713-758.
86. Mullen A.C., Hutchins A.S., High F.A., Lee H.W., Sykes K.J., Chodosh L.A., Reiner S.L. Hlx is induced by and genetically interacts with T-bet to promote heritable T(H)1 gene induction. Nat. Immunol. 2002, 3:652-658.
87. Lee D.U., Agarwal S., Rao A. Th2 lineage commitment and efficient IL-4 production involves extended demethylation of the IL-4 gene. Immunity 2002, 16:649-660.
88. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
89. Akimzhanov A.M., Yang X.O., Dong C. Chromatin remodeling of interleukin-17 (IL-17)-IL-17F cytokine gene locus during inflammatory helper T cell differentiation. J. Biol. Chem. 2007, 282:5969-5972.
90. Floess S., Freyer J., Siewert C., Baron U., Olek S., Polansky J., Schlawe K., Chang H.D., Bopp T., Schmitt E., Klein-Hessling S., Serfling E., Hamann A., Huehn J. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 2007, 5:e38.
91. Richardson B. Effect of an inhibitor of DNA methylation on T cells. II. 5-Azacytidine induces self-reactivity in antigen-specific T4+ cells. Hum. Immunol. 1986, 17:456-470.
92. Richardson B., Scheinbart L., Strahler J., Gross L., Hanash S., Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 1990, 33:1665-1673.
93. Lu Q., Wu A., Tesmer L., Ray D., Yousif N., Richardson B. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J. Immunol. 2007, 179:6352-6358.
94. Richardson B. DNA methylation and autoimmune disease. Clin. Immunol. 2003, 109:72-79.
95. Deng C., Lu Q., Zhang Z., Rao T., Attwood J., Yung R., Richardson B. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum. 2003, 48:746-756.
96. Sawalha A.H., Jeffries M., Webb R., Lu Q., Gorelik G., Ray D., Osban J., Knowlton N., Johnson K., Richardson B. Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients. Genes Immun. 2008, 9:368-378.
97. Gorelik G., Fang J.Y., Wu A., Sawalha A.H., Richardson B. Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazine-induced lupus. J. Immunol. 2007, 179:5553-5563.
98. Renaudineau Y., Youinou P. Epigenetics and autoimmunity, with special emphasis on methylation. Keio J. Med. 2011, 60:10-16.